MAP2K1 and cancer: Nevertheless, the efficacies of our combination strategy are at least 4-fold: (I) reprogramming of immunosuppressive macrophages, (II) exploitation of the pleiotropic effects of interferons, cytokines, and pro-apoptotic molecules from reprogrammed macrophages, (III) maintenance of TLR7-based immunomodulatory effects in pDCs, and (IV) maintenance of MEK1/2 inhibitor-based antineoplastic roles in RAS/RAF-mutated cancers.